Navigation Links
Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014
Date:8/24/2014

France
+33 (0) 1 70 77 09 44
UK
+44 (0) 203 367 9453
U.S.
+1 866 907 5928

Alirocumab is currently under clinical development and its safety and efficacy have not been fully evaluated by any regulatory authority.

About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs.  Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.  Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York, that discovers, invents, develops, manufactures, and commercializes biologic medicines for the treatment of serious medical conditions.  Regeneron commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts.  These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, ope
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron Announces Upcoming 2014 Investor Conference Presentations
2. Regeneron Reports Second Quarter 2014 Financial and Operating Results
3. Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
4. Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration
5. Regeneron Announces Upcoming 2013 Investor Conference Presentation
6. Sanofi and Regenerons Dupilumab Named "Clinical Advance of the Year" by Scrip Intelligence
7. Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
8. Regeneron Reports Third Quarter 2013 Financial and Operating Results
9. Regeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer
10. Regenerons Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentechs Lucentis
11. Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
(Date:12/24/2014)... and LONDON , December ... orthopedic industry are expected to grow at an average ... terms of value and volume. Hip, knee and spine ... world while in emerging economies they have a lower ... are challenging the use of composites. Non-metallic orthopedic devices ...
(Date:12/24/2014)... DALLAS , December 24, 2014 /PRNewswire/ ... Research Report on Global Disposable Syringe Industry ... to its online business intelligence library. ... Global Disposable Syringe Industry is a professional ... Syringe market.  For overview analysis, the report ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Facial Plastic Surgeon, Davis B. Nguyen, MD is ... ARTISS Fibrin Sealant has been approved by the FDA ... seven prominent plastic surgeons in the country who, in ... the benefits of using fibrin glue in facelifts. ...
... Galenea Corp., a leader in the rapidly emerging ... a paper in PLoS ONE demonstrating the ... Assay) system, Galenea,s proprietary technology that enables high throughput ...  Changes in synaptic function are now believed to play ...
Cached Medicine Technology:Facial Plastic Surgeon, Dr. Davis B. Nguyen Announces Fibrin Glue Approved by FDA for Use In Facelifts 2Galenea Announces Publication Describing High Throughput Screening System for Modulators of Synaptic Function 2Galenea Announces Publication Describing High Throughput Screening System for Modulators of Synaptic Function 3
(Date:12/26/2014)... Cooking and warming equipment has ... This score reflects slightly positive negotiation conditions for buyers, ... switching costs and a low level of price volatility. ... of substitutes for cooking and warming equipment and high ... key inputs in the production process of this equipment,” ...
(Date:12/26/2014)... “Many people become overwhelmed by the thought of ... phone calls with insurance companies,” The Jones Firm explains ... free eBook on pedestrian and bicycle accidents . ... auto accident claims assures the injured individual that a ... their case while they focus on recovering. , ...
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... A child spikes a high fever, sometimes as high as ... to the emergency room, the hospital runs test after test, ... Many families though no one knows how many ... like clockwork, arent accompanied by any obvious symptoms and dont ...
... Edward G.,Rendell today released the text of his March ... for MCare fund assessment payments:, Dear Health Care ... the state was in a unique,position to extend MCare ... affordable health care for hundreds of thousands of uninsured,Pennsylvanians., ...
... E.,Lattman, currently Dean of Research and Graduate Education in ... Hopkins University (JHU), has,been appointed Chief Executive Officer and ... assume the,position on July 1, 2008. A published author ... and JHU and at JHU has served,as department chair ...
... However, patients stay on the new medications longer, study ... so-called second-generation antipsychotics are no better than the older ... a new study finds. , However, it appears that ... likely to continue using them than haloperidol, the study ...
... 28 The Raleigh County League of,Democratic Women will ... on,presidential candidates Hillary Clinton and Barack Obama., "We,re ... Susman said. "But each one will be represented by ... 1 debate will be held at 6 p.m. Tuesday ...
... 16 multi-detector CT (MDCT); theres no need for an additional ... by researchers at the University of Maryland Medical Center and ... The study showed that whole body MDCT is just as ... blunt trauma patients would undergo whole-body MDCT and if there ...
Cached Medicine News:Health News:Mysterious fevers of unknown origin: Could surgery be a cure? 2Health News:Governor Rendell Writes to Physicians to Explain MCare Fund Assessment Deadline 2Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 2Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 3Health News:New Drugs No Better Than Older Ones for Schizophrenia 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 3Health News:Whole body MDCT just as 'good' as neck MDCT angiography in diagnosing head and neck injuries 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: